Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

• Status: Recruiting
• Trial end date: 2022-12-17
• Target enrollment: 0
• Participant gender: All

Summary

This research study will evaluate the effectiveness and estimate the feasibility of administering an investigational drug called 'CN-105' (the study drug), to prevent postoperative cognitive decline, delirium (serious confusion) and underlying brain inflammatory and brain activity changes in adults 60 years and older undergoing surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Miles Berger, MD PhD

Criteria

Inclusion Criteria:

• Age ≥ 60

• Ability to speak English

• Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last > 2 hours; due to be admitted to the hospital following surgery

Exclusion Criteria:

• Inmate of a correctional facility

• Scheduled to receive systemic chemotherapy between the time of the two cognitive testing sessions

• Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other clinical contraindication known ahead of time.

• Inappropriate for study inclusion based on the judgement of the principal investigator.

• If a patient undergoes major head trauma that occurs between the times of the two cognitive testing sessions, then they will be withdrawn from the study.